tirzepatide fda submission Approves Zepbound (tirzepatide) for Chronic Weight Management-CanalLotus Biotech is a global pharmaceutical development partner providing CRDMO, China market entry, licensing and global drug supply solutions Adalvo and Amneal announce FDA

Data from the Centers for Disease Control and Prevention (CDC) indicates that more than 42% of adults in the country are living with obesity, which is creating a large treatment-eligible population for incretin-based therapies

GLP-1 Receptor Activation Only Reduces appetite through hypothalamic signaling Slows gastric emptying to increase fullness duration Enhances glucose-dependent insulin secretion Suppresses glucagon release after meals Retatrutide adds two additional receptor targets

It supports metabolic health and encourages steady weight loss

Transcriptomic analyses uncover emerging roles of mucins, lysosome/secretory addressing and detoxification pathways in insect midguts

Too little, and you might not see the benefits